The inhibition of MET alone has been demonstrated to have limited efficacy in colon cancer; although the Src inhibitor, dasatinib, reduced MET autophosphorylation and decreased MET phosphorylation by stimulating factors, the inhibition is not complete. This evidence concerns the gene MET and malignant colon neoplasm.